Product Description
Mechanisms of Action: PA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Croatia | Iceland | Ireland | Latvia | Netherlands | Poland | Portugal | Romania | Switzerland
Approved Indications: None
Known Adverse Events: None
Company: Leiden University Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Atrial Fibrillation|Hypertension|Acute Coronary Syndrome|Stroke
Phase 3: Aneurysm, Ruptured|Type 1 Diabetes|Arthritis, Rheumatoid|Hypertension|Pulmonary Heart Disease|Pulmonary Embolism|Pulmonary Infarction|Myocardial Infarction|Embolism and Thrombosis|Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-517236-22-00 |
PROTECT-U | P3 |
Recruiting |
Aneurysm, Ruptured |
2029-06-01 |
2025-05-02 |
Treatments |
|
2024-516643-64-00 |
APHP240889 | P3 |
Not yet recruiting |
Embolism and Thrombosis|Pulmonary Embolism|Myocardial Infarction|Pulmonary Heart Disease|Pulmonary Infarction|Stroke |
2028-11-01 |
|||
2010-024448-13 |
ASPIRETENSION II | P3 |
Active, not recruiting |
Hypertension |
2012-08-18 |
2022-03-13 |
Treatments |
|
2006-001359-36 |
ASPIRETENSION | P3 |
Active, not recruiting |
Arthritis, Rheumatoid|Hypertension|Type 1 Diabetes |
2006-11-02 |
2022-03-12 |
Treatments |
|
2024-513092-40-00 |
114180 | P4 |
Recruiting |
Stroke |
2031-09-02 |
2025-05-02 |
Treatments |
|
2024-516039-28-00 |
BA-SCAD | P4 |
Active, not recruiting |
Unknown |
2026-02-28 |
2025-05-02 |
Treatments |
|
2019-004805-28 |
WOEST 3 trial | P4 |
Completed |
Atrial Fibrillation|Acute Coronary Syndrome |
2025-02-17 |
2025-05-06 |
Treatments|Trial Status |
|
NCT01379079 |
ASPIRETENSION | P4 |
Completed |
Hypertension |
2013-10-01 |
2025-02-07 |
Primary Endpoints |
|
2007-004354-90 |
2007-004354-90 | P4 |
Active, not recruiting |
Unknown |
2008-03-03 |
2022-03-12 |
Treatments |